#1 out of 2
health1d ago
Some of Pharma's Biggest Brands Face a New Reality
- Medicare added 15 drugs to its latest price negotiation list, expanding government leverage over pharma pricing.
- Pfizer, Novartis and Lilly drugs are now part of the government’s next round of price talks.
- Any negotiated prices would not take effect until 2028, limiting immediate revenue impact.
- Medicare targets large, established drugs with steady cash flow to pressure pricing long-term.
- The move signals ongoing pricing pressure for top pharma brands amid federal negotiation.
- The article emphasizes a broader trend of government influence over drug pricing.
- The Reuters-originated piece notes a shift in Medicare negotiations impacting major brands.
- Drugs named include Botox, Orencia, and Biktarvy among others in the list.
- The article cites Medicare beneficiary usage and spending associated with the drugs on the list.
- The timing detail clarifies no price changes until 2028 despite ongoing negotiations.
Vote 0
:max_bytes(150000):strip_icc():focal(753x340:755x342)/Rob-Gronkowski-Novartis-012826-e6d1a6dc5b50469c86dc7dd383dd6442.jpg)